Advancing Product Candidates
from Our Own Pipeline

PRINT® Technology

A Simple Elegant Solution for Addressing Challenges in Drug Delivery

Strategic Collaborations

Actively Partnering with
World-class Collaborators

Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary PRINT® technology to transform the lives of patients. Currently, Liquidia is focused on the development of two product candidates using its PRINT® particle engineering platform: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain.

Improving health with uniform drug particles

Liquidia precisely engineers drug particles in a virtually unlimited number of ways to transform the lives of patients. Watch the video to see how we do it. The precision of our PRINT technology is designed to improve the safety, efficacy and performance of a wide range of therapies, while reducing manufacturing complexity and cost.

© 2020 Liquidia Technologies